TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06291285
Drug: Decitabine-THU
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orally administered immediate release tablets.
Study: NCT06291285
Drug: Decitabine-THU
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orally administered delayed release capsules.
Study: NCT05727657
Drug: Satralizumab
Normalized name: SATRALIZUMAB
DrugBank: Satralizumab (DB15762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 120mg subcutaneous Day 0 and Day 14
Study: NCT04713982
Drug: Deutetrabenazine
Normalized name: Deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maximum dose of 48mg/day or up to 36 mg/d if receiving a strong CYP2D6 inhibitor
Study: NCT05498610
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will get 1 injections of semaglutide. It will be injected with a needle into a skin fold on the abdomen.~The study will last for a maximum of 72 days
Study: NCT06486025
Drug: maintenance magnesium sulphate1g/h
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Women will receive a routine loading infusion of 5 g of MgSO4 over 20 minutes, followed by a maintenance dose rate of 1 g/h.
Study: NCT06486025
Drug: maintenance magnesium sulphate2g/h
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Women will receive a routine loading infusion of 5 g of MgSO4 over 20 minutes, followed by a maintenance dose rate of 2 g/h.
Study: NCT05008926
Drug: Naloxegol
Normalized name: Naloxegol
DrugBank: Naloxegol (DB09049)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administration of Naloxegol 25 mg per day by nasogastric tube (SNG) or orogastric tube (SOG). The administration should be started within the first 24 hours after the patient is admitted to intensive care and continued for the duration of the administration of the morphine derivative and until 48 hours after its discontinuation.
Study: NCT06234462
Drug: Amantadine
Normalized name: Amantadine
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants that have been randomized to the study group will be instructed to begin taking amantadine on the day after this study visit. They will self-administer amantadine 100 mg twice daily (morning and noon) for four weeks
Study: NCT05140694
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin 10 mg p.o. once daily (available to control over \~25mg)
Study: NCT05140694
Drug: Dulaglutide
Normalized name: DULAGLUTIDE
DrugBank: Dulaglutide (DB09045)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dulaglutide 0.75mg s.c. once a week (available to control over \~1.5mg)
Study: NCT05140694
Drug: Empagliflozin and Dulaglutide
Normalized name: Dulaglutide
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin 10 mg p.o. once daily with Dulaglutide 0.75mg s.c. once weekly
Study: NCT04874129
Drug: YYC506-T and YYC506-A (phase 1)
Normalized name: (T,G)-A-L
DrugBank: Glatiramer (DB05259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator
Study: NCT04874129
Drug: YYC506-T and YYC506-A (phase 2)
Normalized name: (T,G)-A-L
DrugBank: Glatiramer (DB05259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator
Study: NCT05284604
Drug: Mesenchymal Stem Cells (MSCs)
Normalized name: Autologous adipose derived mesenchymal stem cells (MSCS)
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The MSCs are recovered from bone marrows of healthy donors. Each donor is carefully screened for pathogens to assure the product is safe. The MSCs are strictly compliant with FDA standards under Current Good Manufacturing Practice (cGMP) regulations.
Study: NCT00000649
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000649
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04858516
Drug: palbociclib and exemestane plus trastuzumab and pyrotinib
Normalized name: Exemestane
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Neoadjuvant treatment with palbociclib and exemestane plus trastuzumab and pyrotinib in ER-positive, HER2-positive breast cancer
Study: NCT06788990
Drug: Ficerafusp alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Investigational
Study: NCT06788990
Drug: Pembrolizumab (KEYTRUDA®)
Normalized name: pembrolizumab Injection [Keytruda]
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Immunotherapy agent used in combination with investigational agent
Study: NCT05641337
Drug: Insulin Degludec and Insulin Aspart
Normalized name: insulin degludec and insulin aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The hypoglycemic scheme of the experimental group was that the initial dose of Insulin Degludec and Insulin Aspart was 0.3U/kg multiplied by the patient's weight, plus 5 mg of linagliptin and 0.5 g of metformin three times a day. The control group was treated with traditional four needle insulin.
Study: NCT06078241
Drug: Intravenous lidocaine infusion
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine infusion
Study: NCT06403787
Drug: Aerobic exercise + Ginkgo Biloba Extract
Normalized name: Ginkgo biloba extract
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 weeks of intervention for the participants, divided into 3 stages implementing an exercise adaptation period. The adaptation period will span the first 4 weeks of the intervention, during which participants will be brought to an intensity between 50% and 60% of their maximum heart rate (HRmax). From week 5 to 8, the HRmax range will be increased from 60% to 70%, and during the last 4 weeks, it will be maintained at 70% of HRmax combined with 240 mg of LIFE EXTENSION® brand ginkgo biloba extract in 120 mg tablets
Study: NCT06403787
Drug: Aerobic exercise + Calcined magnesia (placebo)
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 weeks of intervention for the participants, divided into 3 stages implementing an exercise adaptation period. The adaptation period will span the first 4 weeks of the intervention, during which participants will be brought to an intensity between 50% and 60% of their maximum heart rate (HRmax). From week 5 to 8, the HRmax range will be increased from 60% to 70%, and during the last 4 weeks, it will be maintained at 70% of HRmax combined with calcined magnesia (homogenized to the same weight of ginkgo biloba)
Study: NCT06403787
Drug: Aerobic exercise + Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 weeks of intervention for the participants, divided into 3 stages implementing an exercise adaptation period. The adaptation period will span the first 4 weeks of the intervention, during which participants will be brought to an intensity between 50% and 60% of their maximum heart rate (HRmax). From week 5 to 8, the HRmax range will be increased from 60% to 70%, and during the last 4 weeks, it will be maintained at 70% of HRmax combined with 20 mg of atorvastatin
Study: NCT06068868
Drug: ABBV-787
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) Infusion
Study: NCT04944121
Drug: Sodium Chloride 0.9%
Normalized name: SODIUM CHLORIDE 0.9% INJ
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.9% sodium chloride administered by intravenous infusion
Study: NCT06305702
Drug: inetetamab
Normalized name: Inetetamab
DrugBank: Inetetamab (DB17457)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8mg/kg iv day 1 followed by 6mg/kg iv day 1, cycled every 21 days
Study: NCT05306340
Drug: Giredestrant
Normalized name: Giredestrant
DrugBank: Giredestrant (DB19125)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive treatment with giredestrant 30 milligrams (mg) orally once a day (QD) on Days 1-28 of each 28-day cycle until unacceptable toxicity or disease progression as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1).
Study: NCT04607668
Drug: Trilaciclib
Normalized name: Trilaciclib
DrugBank: Trilaciclib (DB15442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trilaciclib diluted in dextrose 5% in water or normal saline (sodium chloride solution 0.9%) administered by IV infusion over approximately 30 (±10) minutes no more than 4 hours prior to each Day 1 chemotherapy administration. Second dose of trilaciclib was administered on Day 2.
Study: NCT05306340
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If exemestane is chosen as the physician's choice of endocrine therapy, the participant will receive exemestane at a dose of 25 mg orally once a day (QD) on Days 1-28 of each 28-day cycle or as per local label, until unacceptable toxicity or disease progression as determined by investigator according to RECIST v1.1.
Study: NCT05306340
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: If fulvestrant is chosen as the physician's choice of endocrine therapy, the participant will receive fulvestrant in the clinic at a dose of 500 mg intramuscularly on Day 1 and Day 15 of Cycle 1, then Day 1 of each cycle thereafter (1 cycle is 28 days) or as per local prescribing information, until unacceptable toxicity or disease progression as determined by investigator according to RECIST v1.1.
Study: NCT05306340
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If tamoxifen is chosen as the physician's choice of endocrine therapy, the participant will receive tamoxifen at a dose of 20 mg orally QD on Days 1-28 of each 28-day cycle or as per local prescribing information, until unacceptable toxicity or disease progression as determined by investigator according to RECIST v1.1.
Study: NCT05306340
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive treatment with everolimus 10 mg orally QD during each 28-day cycle until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.
Study: NCT05306340
Drug: Dexamethasone Mouth Rinse
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A compounded alcohol-free mouthwash of dexamethasone (0.5 mg in 5 mL) will be supplied, where feasible. It is strongly recommended for prophylaxis or treatment of stomatitis/mucositis. Participants should use the alcohol-free mouthwash of dexamethasone four times QD for 8 weeks started concurrently with study treatment, and use it reactively thereafter with the first appearance of symptoms.
Study: NCT05056246
Drug: AMG 133
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for SC injection
Study: NCT05319431
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will receive lenvatinib until disease progression or for a maximum of 24 months
Study: NCT05001880
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05001880
Drug: Hyperthermic Intraperitoneal Chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo HIPEC
Study: NCT05001880
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT04573920
Drug: Atrasentan
Normalized name: ATRASENTAN
DrugBank: Atrasentan (DB06199)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet
Study: NCT04714320
Drug: IONIS-AGT-LRx
Normalized name: IONIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IONIS-AGT-LRx administered by SC injection.
Study: NCT06787911
Drug: Donafeib with Sintilimab
Normalized name: Primatene with ephedrine Pill
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive Donafenib and PD-1 antibody Sintilimab
Study: NCT04977778
Drug: Stannous Fluoride (SF) Mouthwash
Normalized name: stannous fluoride Mouthwash
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stannous Fluoride (SF) Mouthwash
Study: NCT04120766
Drug: Nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg po qd
Study: NCT04720157
Drug: 177Lu-PSMA-617
Normalized name: 177Lu-PSMA-617
DrugBank: Lutetium Lu-177 vipivotide tetraxetan (DB16778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered intravenously once every 6 weeks (1 cycle) for 6 cycles
Study: NCT04720157
Drug: 68Ga-PSMA-11
Normalized name: 68Ga-Psma-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dose of approx. 150 Megabecquerel (MBq) at screening and at time of centrally confirmed rPD
Study: NCT06431763
Drug: Inclisiran sodium
Normalized name: inclisiran sodium
DrugBank: Inclisiran (DB14901)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 300 mg s.c. administered at day 1 and day 90
Study: NCT06431763
Drug: BPA
Normalized name: DGEBPA
DrugBank: Bisphenol A (DB06973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mg daily per oral
Study: NCT05380063
Drug: De-escalated Dual Antiplatelet Therapy
Normalized name: Tums Dual Action
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ticagrelor (90mg twice daily) + aspirin (100 mg once daily) during first 3 months post CABG, then switching to aspirin (100 mg once daily) + placebo (twice daily) for 9 months.
Study: NCT05380063
Drug: Dual Antiplatelet Therapy
Normalized name: Tums Dual Action
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor (90mg twice daily) + aspirin (100 mg once daily) for 1 year post CABG.
Study: NCT06501625
Drug: Ivosidenib
Normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two 250 mg tablets, totaling 500 mg, administered orally once daily, taken continuously throughout treatment duration
Study: NCT06501625
Drug: Durvalumab (for the first 8, 21-day, cycles)
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1500mg intravenous (IV) infusion every 3 weeks, for a maximum of 8 (21-day) cycles
Study: NCT06501625
Drug: Gemcitabine (for the first 8, 21-day, cycles)
Normalized name: Gemcitabine for Injection
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2 IV infusion on days 1 and 8 of every 21-day cycle, for a maximum of 8 cycles
Study: NCT06501625
Drug: Cisplatin (for the first 8, 21-day, cycles)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/m\^2 IV infusion on days 1 and 8 of every 21-day cycle, for a maximum of 8 cycles
Study: NCT06501625
Drug: Durvalumab (starting from cycle 9)
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1500mg intravenous (IV) infusion every 4 weeks, starting from cycle 9. Cycles are 28 days long, starting Cycle 9.
Study: NCT06501625
Drug: Ivosidenib Recommended Combination Dose (RCD)
Normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RCD administered orally once daily, taken continuously throughout treatment duration
Study: NCT06790212
Drug: Ivonescimab
Normalized name: Ivonescimab
DrugBank: Ivonescimab (DB18931)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg/kg Q3W，D1
Study: NCT06590324
Drug: Apabetalone
Normalized name: Apabetalone
DrugBank: Apabetalone (DB12000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-mg capsule, twice daily oral administration with meals
Study: NCT06790212
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin，130mg/m2，D1，Q3W；
Study: NCT06094010
Drug: Baloxavir Marboxil
Normalized name: Baloxavir Marboxil
DrugBank: Baloxavir marboxil (DB13997)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Baloxavir marboxil will be administered as oral suspension either as 2 milligrams per kilograms (mg/kg) (if weight less than 20 kg), or 40 mg (if weight more than or equal to 20 kg to less than 80 kg) or 80 mg (if weight more than or equal to 80 kg).
Study: NCT05887375
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sugammadex will be used to reverse rocuronium neuromuscular blockade (NMB). Dose will be according to participant actual body weight.
Study: NCT05887375
Drug: Neostigmine
Normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neostigmine will be used to reverse rocuronium NMB. Dose will be according to participant actual body weight.
Study: NCT05887375
Drug: Glycopyrrolate
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate will be co-administered with neostigmine during reversal of rocuronium NMB. Dose will be according to participant actual body weight.
Study: NCT05887375
Drug: Rocuronium
Normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To achieve NMB, participants will receive the steroidal neuromuscular blocking agent Rocuronium Bromide administered via IV infusion and dosed according to participant actual body weight. It will be used per label to maintain muscle relaxation as an adjunct to general anesthesia.
Study: NCT05700669
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib is given orally in combination with AsiDNA
Study: NCT05267262
Drug: R3R01
Normalized name: R3R01
DrugBank: R3R01 (DB18078)
Approvals — FDA: no, EMA: no, PMDA: no
Description: R3R01 administered orally for 12 weeks
Study: NCT06784973
Drug: Obeldesivir
Normalized name: Obeldesivir
DrugBank: Obeldesivir (DB18821)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06784973
Drug: Obeldesivir Placebo
DrugBank: Obeldesivir (DB18821)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06787131
Drug: ZE50-0134 or placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100 mg ZE50-0134 or placebo
Study: NCT06787131
Drug: Itraconazole (200 mg)
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole 200 mg twice per day on Day-4 and once per day on Days-3 to 8, inclusive
Study: NCT06025916
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 ml of oral solution TA (100mg/ml)
Study: NCT06787131
Drug: ZE50-0134 or placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 200 mg ZE50-0134 or placebo
Study: NCT06787131
Drug: ZE50-0134 or placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 400 mg ZE50-0134 or placebo
Study: NCT06787131
Drug: ZE50-0134 or placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 800 mg ZE50-0134 or placebo
Study: NCT06787131
Drug: ZE50-0134 or placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1600 mg ZE50-0134 or placebo
Study: NCT05857644
Drug: PF-07923568
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One time dose of 4 capsules taken orally.
Study: NCT06124378
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg on Day 1 every 3 weeks and repeat for 2 or 4 cycles. The incidence of adverse events with Tislelizumab is relatively low. The Tislelizumab dose adjustment was implemented according to the prescribing information.
Study: NCT06124378
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 130mg/m2 on Day 1 every 3 weeks and repeat for 2 or 4 cycles. The dose reduction protocol for oxaliplatin-induced toxicity was implemented according to the study in British Journal of Cancer (2018) 118:1322-1328.
Study: NCT03994874
Drug: PolyCore (Polydextrin, L-Carnitine, D-xylitol)
Normalized name: Clinker Polypore Fruiting Body
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single nightly exchange, with 2 liters PolyCore solution, lasting 12-14 hours. Patients should remain on their prescribed heart failure medications and the same dosing schedule for the duration of the study unless investigators determine medically necessary to change.
Study: NCT04776395
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04776395
Drug: Iberdomide Hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Iberdomide (DB12101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05479994
Drug: BGB-11417
Normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05369208
Drug: Avatrombopag Oral Tablet
Normalized name: avatrombopag Oral Tablet
DrugBank: Avatrombopag (DB11995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Avatrombopag 20 mg given once daily (initial dose). Dosage adjustments were determined by the physician to maintain a platelet count between 50 x 10\^9 to 200 x 10\^9 as defined in the protocol and in accordance with overseas labeling.
Study: NCT05958875
Drug: Clozapine
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants are randomized to clozapine or second-line antipsychotics. When randomised to clozapine, they will receive clozapine for six weeks.
Study: NCT05817890
Drug: Fadraciclib
Normalized name: Samuraciclib
DrugBank: Samuraciclib (DB16061)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label Study of the Absorption, Metabolism, and Excretion of \[14C\]-CYC065 Following a Single Oral Dose in Healthy Male Subjects
Study: NCT06199700
Drug: Esketamine hydrochloride
Normalized name: esketamine hydrochloride
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous infusion of Ketamine